Pharmacokinetics of Isavuconazole in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation (ECMO) Support: A Prospective Exploratory Observational Study
Pharmaceutics · 24.08.2026 · 18 (9) · 1049
DOI: 10.3390/pharmaceutics18091049 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 24.08.2026. Verfasst von Alba Escolà-Rodríguez und 13 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy Department, Division of Medicines, Hospital Clínic de Barcelona, 08036 Barcelona, Spain. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Catalan Society of Clinical Pharmacy (SCFC).
Abstract (Originalsprache)
Background
Isavuconazole, a broad-spectrum triazole antifungal, exhibits high lipophilicity and extensive plasma protein binding, properties that may predispose it to sequestration within extracorporeal membrane oxygenation (ECMO) circuits. This study aimed to characterize the pharmacokinetics (PK) of isavuconazole and to evaluate drug sequestration within the ECMO circuit in critically ill patients receiving ECMO support.
Methods
We conducted a prospective, exploratory, single-center observational study including critically ill patients receiving ECMO (veno-venous (VV) or veno-arterial (VA)) and treated with intravenous isavuconazole. Serial blood samples were collected simultaneously from the patient’s arterial line and from pre- and post-membrane oxygenator sampling sites. Non-compartmental analysis was performed on arterial line samples to estimate PK measures, and concentration differences across sampling sites were analyzed to estimate circuit-related drug loss. PK/pharmacodynamic (PD) target attainment was assessed using established efficacy thresholds (AUC0–24/MIC ≥ 25 and Cmin > 2 mg/L).
Results
A total of 41 plasma samples from 3 critically ill patients (2 VV-ECMO, 1 VA-ECMO) were included in the analysis. Limited, component-specific isavuconazole loss was observed in tubing and connectors (6.62% ± 20.8%, p = 0.294) and across the entire ECMO circuit (7.74% ± 20.2%, p = 0.211). Likewise, no relevant concentration difference was detected across the membrane oxygenator (0.849% ± 6.15%, p = 0.642). Interindividual variability was observed across PK parameters, particularly in measures of elimination and distribution. All patients achieved predefined PK/PD efficacy targets, with mean Cmin and AUC0–24/MIC of 3.07 ± 0.261 mg/L and 85.3 ± 4.03, respectively, and none exceeded the established toxicity threshold.
Conclusions
Preliminary results showed variable concentration differences across ECMO sampling sites, with no consistent pattern of isavuconazole loss across the ECMO circuit under the conditions evaluated. All patients achieved predefined PK/PD efficacy targets using currently recommended dosing regimens; however, interindividual PK variability was observed, supporting the potential value of therapeutic drug monitoring (TDM) to guide individualized dosing decisions in this population. Larger population PK studies are warranted to further characterize determinants of isavuconazole exposure during ECMO support and refine evidence-based dosing strategies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Pharmacy Department, Division of Medicines, Hospital Clínic de Barcelona, 08036 Barcelona, Spain.
- Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, 08036 Barcelona, Spain.
- Department of Cardiovascular Surgery, Hospital Clínic de Barcelona, 08036 Barcelona, Spain.
- Respiratory Intensive and Intermediate Care Unit, Department of Respiratory Medicine, Hospital Clínic de Barcelona, 08036 Barcelona, Spain.
- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, 08036 Barcelona, Spain.
- Medical Intensive Care Unit, Hospital Clínic de Barcelona, 08036 Barcelona, Spain.
ORCID-Profile: Alba Escolà-Rodríguez, Elena Sandoval, Jorge Moisés, Adrián Téllez Santoyo, Jaime I Sainz de Medrano, Marta Hernández Meneses, Sabina Herrera, Pedro Castro, Dolors Soy Muner, Carla Bastida
Förderung
- Catalan Society of Clinical Pharmacy (SCFC)
Zitieren
APA
Escolà-Rodríguez, A., Sandoval, E., Moisés, J., Téllez Santoyo, A., Carramiñana, A., Sainz de Medrano, J. I., Espinosa, C., Roca, C., Hernández Meneses, M., Herrera, S., Brunet Serra, M., Castro, P., Soy Muner, D., & Bastida, C. (2026). Pharmacokinetics of Isavuconazole in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation (ECMO) Support: A Prospective Exploratory Observational Study. Pharmaceutics, 18(9), 1049. https://doi.org/10.3390/pharmaceutics18091049
Vancouver
Escolà-Rodríguez A, Sandoval E, Moisés J, Téllez Santoyo A, Carramiñana A, Sainz de Medrano JI, et al. Pharmacokinetics of Isavuconazole in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation (ECMO) Support: A Prospective Exploratory Observational Study. Pharmaceutics. 2026;18(9):1049. doi:10.3390/pharmaceutics18091049
BibTeX
@article{EscolRodrguez2026,
author = {Escolà-Rodríguez, Alba and Sandoval, Elena and Moisés, Jorge and Téllez Santoyo, Adrián and Carramiñana, Albert and Sainz de Medrano, Jaime I and Espinosa, Cristina and Roca, Carlos and Hernández Meneses, Marta and Herrera, Sabina and Brunet Serra, Mercè and Castro, Pedro and Soy Muner, Dolors and Bastida, Carla},
title = {Pharmacokinetics of Isavuconazole in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation (ECMO) Support: A Prospective Exploratory Observational Study},
journal = {Pharmaceutics},
year = {2026},
volume = {18},
number = {9},
pages = {1049},
doi = {10.3390/pharmaceutics18091049}
}
EUVIMED